A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects with Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides
This study is being done to test the safety and efficacy of TTI-621 in patients with solid tumors that can be punctured with a needle through the skin or in patients that have been diagnosed with mycosis fungoides (MF, a form of cutaneous T-cell lymphoma).
Mycosis fungoides (MF, a form of cutaneous T-cell lymphoma)
Solid tumor cancer
1. Men and women 18 years or older
2. Recurrent or metastatic solid tumors
3. Adequate organ function
4. Other criteria apply
18 - 100
Healthy Volunteers Needed
Duration of Participation
Participants will receive the study drug for up to 4 injections as long as their cancer does not get worse and they do not develop side effects that they cannot tolerate. Participants will have scans collected 6, 12, and 18 weeks after the last dose of the study drug and a follow-up visit 30 days after the last dose of study drug. After the follow-up visit, participants will be contacted by phone every 3 months for 1 year.
Knight Clinical Trials Information Line
Trillium Therapeutics, Ltd.